- AP26113 is "a much stronger contender than Novartis' (NVS -0.3%) LDK378, given the cleaner safety profile, and [we] anticipate meaningful uptake in the crizotinib-refractory setting," Oppenheimer's David Ferreiro says, referring to Ariad's (ARIA -3.6%) tyrosine kinase inhibitor and its prospects in ALK+ non-small cell lung cancer.
- Ferreiro is also upbeat on Iclusig in CML, saying he believes the drug "will acheive significant adoption in the first-line setting, despite Gleevec genericization."
- ARIA upgraded to Outperform from Perform, although the target is raised just $1 to $24 — remember, Ferreiro thinks positive AP26113 data is already factored into the stock's price.
- Nevertheless, the stock is weak at the open. It's possible investors are reacting negatively to the following line in the company's ESMO PR: "In three out of 26 patients receiving 180 mg per day of AP26113 in the Phase 2 portion of the trial, early-onset pulmonary symptoms were observed after the first dose of AP26113."
Ariad trades lower after AP26113 news despite Oppenheimer upgrade
Sep 30 2013, 09:36 ET